Trials / Not Yet Recruiting
Not Yet RecruitingNCT07534813
A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study adopts a single-center, single-arm, open-label design. It aims to evaluate the safety and tolerability of GT307 in patients with advanced solid tumors, as well as assess its pharmacokinetic profile and efficacy, and determine the optimal dosage regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT307 injection | GT307 injection to treat advanced solid tumors |
Timeline
- Start date
- 2026-04-30
- Primary completion
- 2028-05-31
- Completion
- 2028-05-31
- First posted
- 2026-04-16
- Last updated
- 2026-04-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07534813. Inclusion in this directory is not an endorsement.